Regulators in the US have finalised a rule that will reduce payments for drugs provided under the 340B programme and introduce site-neutral payments in 2027, according to BioPharma Dive. Hospitals have strongly criticised the decision, which could affect their revenue streams.
This matters for healthcare executives, as the rule changes payment structures and may influence hospital budgets and drug contracting. Leaders in regulated sectors should monitor implementation and prepare for altered reimbursement models.
